---
title: "Eliquis (apixaban) in nonvalvular atrial fibrillation: Safety questions"
description: "Safety questions on Eliquis (apixaban) in nonvalvular atrial fibrillation, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Bleeding management. Questions: What is the Eliquis boxed warning about stopping early and spinal or epidural hematoma? What happens if Eliquis is stopped early or interrupted? What happens after an Eliquis overdose? Who should not take Eliquis (contraindications)? 3 further questions follow. 7 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/safety"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Eliquis (apixaban) in nonvalvular atrial fibrillation: Safety questions

Manufacturer: Bristol-Myers Squibb Company; Pfizer Inc  
Prescribing information: [Eliquis](https://packageinserts.bms.com/pi/pi_eliquis.pdf)

## Safety

<a id="eliquis-boxed-warning"></a>

### What is the Eliquis boxed warning about stopping early and spinal or epidural hematoma?

> “WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA
>
> (A) Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.
>
> (B) Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:
>
> use of indwelling epidural catheters
> concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants
> a history of traumatic or repeated epidural or spinal punctures
> a history of spinal deformity or spinal surgery
> optimal timing between the administration of ELIQUIS and neuraxial procedures is not known
>
> Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.
>
> Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated.”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=WARNING%3A%20%28A%29%20PREMATURE%20DISCONTINUATION%20OF,anticoagulated%20or%20to%20be%20anticoagulated.)

<a id="eliquis-stopping-early"></a>

### What happens if Eliquis is stopped early or interrupted?

> “Increased Risk of Thrombotic Events after Premature Discontinuation: Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients. If ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=Increased%20Risk%20of%20Thrombotic%20Events,consider%20coverage%20with%20another%20anticoagulant.)

> “At the end of the ARISTOTLE study, warfarin patients who completed the study were generally 
> maintained on a VKA with no interruption of anticoagulation. ELIQUIS patients who completed 
> the study were generally switched to a VKA with a 2-day period of coadministration of 
> ELIQUIS and VKA, so that some patients may not have been adequately anticoagulated after 
> stopping ELIQUIS until attaining a stable and therapeutic INR. During the 30 days following the 
> end of the study, there were 21 stroke or systemic embolism events in the 6791 patients (0.3%) 
> in the ELIQUIS arm compared to 5 in the 6569 patients (0.1%) in the warfarin arm [see Dosage 
> and Administration (2.4)].”

Source: [ELIQUIS: Prescribing information, page 11, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=11)

<a id="eliquis-overdose"></a>

### What happens after an Eliquis overdose?

> “Overdose of ELIQUIS increases the risk of bleeding [see Warnings and Precautions (5.2)].
> In healthy subjects, administration of activated charcoal 2 and 6 hours after ingestion of 
> a 20-mg dose of apixaban reduced mean apixaban AUC by 50% and 27%, respectively. 
> Thus, administration of activated charcoal may be useful in the management of ELIQUIS 
> overdose or accidental ingestion.
> Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional 
> overdose management recommendations.”

Source: [ELIQUIS: Prescribing information, page 8, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=8)

<a id="eliquis-contraindications"></a>

### Who should not take Eliquis (contraindications)?

> “CONTRAINDICATIONS
> Active pathological bleeding
> Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions)”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=CONTRAINDICATIONS,to%20ELIQUIS%20%28e.g.%2C%20anaphylactic%20reactions%29)

<a id="eliquis-side-effects"></a>

### What are the most common side effects of Eliquis in atrial fibrillation?

> “The most common and most serious adverse reactions reported with ELIQUIS were related to bleeding in adult patients.”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=The%20most%20common%20and%20most,to%20bleeding%20in%20adult%20patients.)

> “The most common reason for treatment discontinuation in ARISTOTLE and AVERROES was for bleeding-related adverse reactions; in ARISTOTLE, this occurred in 1.7% and 2.5% of patients treated with ELIQUIS and warfarin, respectively, and in AVERROES, in 1.5% and 1.3% on ELIQUIS and aspirin, respectively”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=The%20most%20common%20reason%20for,on%20ELIQUIS%20and%20aspirin%2C%20respectively)

> “The safety of ELIQUIS was evaluated in the ARISTOTLE and AVERROES studies [see Clinical 
> Studies (14)], including 11,284 patients exposed to ELIQUIS 5 mg twice daily and 602 patients 
> exposed to ELIQUIS 2.5 mg twice daily. The duration of ELIQUIS exposure was ≥12 months for 
> 9375 patients and ≥24 months for 3369 patients in the two studies. In ARISTOTLE, the mean 
> duration of exposure was 89 weeks (>15,000 patient-years). In AVERROES, the mean duration of 
> exposure was approximately 59 weeks (>3000 patient-years).”

Source: [ELIQUIS: Prescribing information, page 4, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=4)

> “Hypersensitivity reactions (including drug hypersensitivity, such as skin rash, and 
> anaphylactic reactions, such as allergic edema) and syncope were reported in <1% of patients 
> receiving ELIQUIS.”

Source: [ELIQUIS: Prescribing information, page 5, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=5)

## Bleeding management

<a id="eliquis-bleeding-risk"></a>

### Does Eliquis increase the risk of bleeding?

> “Bleeding Risk: ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding.
> Concomitant use of drugs affecting hemostasis increases the risk of bleeding, including aspirin and other antiplatelet agents, other anticoagulants, heparin, thrombolytic agents, SSRIs, SNRIs, and NSAIDs.
> Advise patients of signs and symptoms of blood loss and to report them immediately or go to an emergency room. Discontinue ELIQUIS in patients with active pathological hemorrhage.”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=Bleeding%20Risk%3A%20ELIQUIS%20increases%20the,patients%20with%20active%20pathological%20hemorrhage.)

<a id="eliquis-reversal"></a>

### Is there a reversal agent for Eliquis?

> “An agent to reverse the anti-factor Xa activity of apixaban is available for adults.”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=An%20agent%20to%20reverse%20the,apixaban%20is%20available%20for%20adults.)

> “Additional information for reversal of anticoagulant effect
>
> Prothrombin complex concentrate (PCC), activated prothrombin concentrate or recombinant factor VIIa may be considered but have not been evaluated in clinical studies
> When PCCs are used, monitoring for the anticoagulation effect of ELIQUIS using a clotting test (PT, INR, or aPTT) or anti-factor Xa (FXa) activity is not useful and is not recommended
> Hemodialysis does not appear to have a substantial impact on ELIQUIS exposure
> Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of ELIQUIS
> There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in individuals receiving ELIQUIS
> There is no experience with systemic hemostatics (desmopressin) in individuals receiving ELIQUIS, and they are not expected to be effective as a reversal agent
>
> Activated oral charcoal reduces absorption of ELIQUIS, thereby lowering ELIQUIS plasma concentration”

Source: [ELIQUIS: Dosing & Administration for NVAF, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/dosing/nvaf#:~:text=Additional%20information%20for%20reversal%20of,thereby%20lowering%20ELIQUIS%20plasma%20concentration)

Note: The safety information directs readers to www.andexxa.com for the availability of a reversal agent.

## Related pages
- [Medical information: Eliquis (apixaban): Nonvalvular atrial fibrillation](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation)
- [Indication](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/real-world-evidence)
- [Specific populations](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/access-and-coverage)
